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Chronic liver disease (CLD) is increasing worldwide yet there has been no major advance in eﬀective therapies for almost ﬁve
decades. There is mounting evidence that adult haematopoietic stem cells (HSC) are capable of diﬀerentiating into many types of
tissue, including skeletal and cardiac muscle, neuronal cells, pneumocytes and hepatocytes. These recent advances in regenerative
medicine have brought hope for patients with liver cirrhosis awaiting transplantation. New ﬁndings in adult stem cell biology are
transforming our understanding of tissue repair raising hopes of successful regenerative hepatology. Although all clinical trials to
date have shown some improvement in liver function and CD34+ cells have been used safely for BM transplantation for over 20
years,onlyrandomisedcontrolledclinicaltrialswillbeabletofullyassessthepotential clinical beneﬁtofadultstemcell therapyfor
patients with CLD. This article focuses on the potential of bone marrow stem cells (BMSCs) in the management of CLD and the
unresolved issues regarding their role. We also outline the diﬀerent mechanisms by which stem cells may impact on liver disease.
1.Introduction
The liver has a remarkable capacity to regenerate in response
to injury; however, in severe cases its regenerative capacity
may prove to be insuﬃcient, and the liver injury may
progress to end-stage liver disease (ESLD) and subsequent
l i v e rf a i l u r e .U pt ot w om i l l i o np e o p l es u ﬀer from chronic
liver disease in the UK, many of whom remain unaware of
their illness [1, 2]. Chronic liver disease is the ﬁfth leading
cause of death in the UK after cancer, cardiovascular disease,
stroke, and respiratory disease [2]. Alcoholic liver disease
(ALD), one of the major medical complications of alcohol
abuse, is the commonest cause of ESLD in Europe and North
America and is one of the most controversial indications
for transplantation. Alcohol abuse accounts for 80% of all
liver cirrhosis cases seen in district general hospitals in the
United Kingdom [3] and for a substantial and increasing
proportion of all liver transplants performed. Chronic liver
disease (CLD) due to alcohol abuse continues to rise [4]. In
2005, 4,160 people died in England and Wales from alcoholic
liver disease, an increase of 37% since 1999 [1]. Alcoholic
liver cirrhosis (ALC) has an unfavourable prognosis, with
a mortality of 49% and 90% after 1 and 15yr of followup,
respectively [5].
At present orthotopic liver transplantation is the only
therapeutic option for patients with acute and chronic
ESLDs. Liver transplantation, however, has the disadvantage
of requiring lifelong immunosuppression and followup,
with 10–15% of patients dying whilst on the waiting list
due to the shortage of donated organs [6]. In 2005, only
one-third of patients waiting for a liver transplant were
transplanted [6]. With the number of donor organs likely
to decrease over the coming decades, research into the
alternative methods of treatment of whole-organ transplant
is essential. Hepatocyte transplantation has been suggested
as an alternative to liver transplantation, especially for
hepatic disorders caused by inherited protein deﬁciency [7].
The widespread application of hepatocyte transplantation,
however, is also limited by organ availability, by problems
with viability of isolated hepatocytes after cryopreservation,
and by the potential formation of hepatocyte aggregates
duringinjectionsubsequentlyobstructingliversinusoidsand
resulting in portal hypertension or fatal emboli.2 International Journal of Hepatology
Recent advances in the understanding of stem cell
biology and plasticity have raised expectations for using
stem cells as a new type of cellular therapy in regener-
ative medicine. In particular, adult hematopoietic stem-
cell (HSC-) based treatment is evolving as a viable clinical
alternative. These cells are capable of diﬀerentiating into
many types of tissues, including skeletal and cardiac muscles,
neuronal cells, pneumocytes, and hepatocytes [8]. Although
stem cell therapy is not classically considered within the
realm of clinical medicine, this technology will become
increasingly important for clinicians in the future.
The BM compartment is largely made up of HSCs,
committed progenitor cells, and noncirculating stromal
cells called mesenchymal stem cells (MSC) which have
the ability to develop into mesenchymal lineages [9, 10].
Haematopoietic stem cells are adult stem cells that can be
identiﬁed by their ability to diﬀerentiate into all blood cell
types and reconstitute the haematopoietic system in a host
that has been lethally myeloablated [11]. It was previously
thought that adult stem cells were lineage restricted, but
recent studies have shown that BM-derived progenitors
participate in the regeneration of ischaemic myocardium
[12], damaged skeletal muscle [13], and neurogenesis [14],
in addition to haematopoiesis. This paper focuses on the
potential of HSCs in the management of CLD, concentrating
on experimental models in animal and human tissue along
with the current status of clinical trials.
2.TheRoleofBoneMarrowStemCells(BMSCs)
inLiverRepair
One of the ﬁrst demonstrations of the ability of BMSCs to
reconstitute liver was reported by Petersen and colleagues in
1999. Lethally irradiated female rats with induced hepatic
injury, treated with 2-aminoacetylﬂuorine to prevent hepatic
proliferation, and were rescued using bone marrow trans-
plants from syngeneic males. The Y-chromosome markers
dipeptidyl peptidase IV enzyme (DPPIV) and L21-6 antigen
were used to identify liver cells of BM origin. This cross-
sex model allowed the identiﬁcation of male liver cells in the
female rats’ livers indicating that BM-derived HSCs have the
capacity to transdiﬀerentiate into hepatocytes [15].
Although evidence of transdiﬀerentiation to hepatocytes
is compelling from animal studies, few have examined this
possibility in humans. Alison and associates detected Y-
chromosome-positive cells in a retrospective analysis of the
livers of9 femalerecipients ofbone marrow transplants from
male donors. Cells were conﬁrmed as being hepatocytes due
to their expression of cytokeratin-8 [16]. The authors also
looked for the presence of Y-chromosome-positive cells in
11 female livers transplanted to male recipients that were
laterremovedduetorecurrentdisease,ﬁndinganumberthat
expressed cytokeratin-8 (0.5%–2%). This conﬁrmed that
circulating extrahepatic stem cells colonise the liver [16].
3. Mechanismof HepatocyteRegeneration
There is much controversy concerning the mechanism by
which BMSCs contribute to hepatocyte regeneration or to
liver repair. Transdiﬀerentiation into hepatocytes represents
genomic plasticity in response to the microenvironment and
has been shown in several experiments in vivo [17–19].
However, some authors have proposed that conversion to
hepatocytes may occur via cell fusion [20, 21]. The so-called
“bystander eﬀect” is postulated to be due to factors secreted
by BMSCs that are chemoattracted to the site of injury,
leading to the stimulation of mitosis of endogenous liver
cells. This mechanism is thought to recruit endogenous BM
for cardiac repair following myocardial infarction following
administration of granulocyte colony-stimulating factor (G-
CSF) [22].
Otherpossibleexplanationsfortargetorganregeneration
and improvement in function include facilitating the release
of vascular endothelial growth factor (VEGF) by stem cells,
thus, increasing the blood supply to cells and helping to
repair damaged tissue [23]. Stem cells may also act by up-
regulating the Bcl-2 gene and suppressing apoptosis [24]o r
by suppressing inﬂammation in the diseased organ via the
interleukin-6 (IL-6) pathway [25]. Both of these processes
are thought to contribute to the regeneration of normal cells
in the damaged organ. Finally, HSCs may stimulate tissue-
speciﬁc stem cells, such as oval cells in the liver, facilitating
regeneration of the target organ [26].
4. AnimalStudies
Jang and colleagues transplanted enriched CD45+ HSCs into
lethally irradiated mice treated with a single dose of carbon
tetrachloride (CCl4)[ 19]. In this model, 7.6% of liver cells
were of donor origin within 7 days of transplantation. There
was early amelioration of liver disease with some improve-
ment in liver function in transplanted mice compared to
controls. The most promising study to date demonstrates
liver disease reversal following transplantation of enriched
HSCs into fumarylacetoacetate hydrolase- (FAH-) deﬁcient
mice, an animal model of tyrosinemia type I [27]. Bone
marrow from metabolically competent donor mice was
transplanted into a lethally irradiated FAH-deﬁcient mouse
strain, resulting in the proliferation of large numbers of
donor LacZ+ hepatocytes and restoration of liver biochem-
ical function. However, an animal study to investigate
whether transplantation of HSCs CD34+ could improve
hepatic ﬁbrosis by their diﬀerentiation into hepatocytes
found diﬀering results [28]. HSCs from human umbilical
cord blood were puriﬁed, transduced with a lentiviral vector
containing the green ﬂuorescent protein (GFP) gene, and
injected via the portal vein into rats with liver cirrhosis
inducedbythefour-monthadministrationofthioacetamide.
Rats were killed at 15 and 60 days following transplantation.
Up to 37% and 22% ﬂuorescent cells were observed in
the blood of control and cirrhotic rats respectively, at 15
days after transplantation. At 60 days after transplantation;
however, ﬂuorescent cells were completely absent from the
blood. Fluorescence was not detected in liver sections at
either15or60daysaftertransplantation.Apolymerasechain
reaction study to detect the GFP gene ruled out silencing
of the transgene. These results suggest that the transplantedInternational Journal of Hepatology 3
cellsdid notengraftintheliverandwereeliminated fromthe
rats.
Oyagi and associates have transplanted MSCs, induced
to adopt hepatocyte phenotype in vitro, intravenously into
nonirradiated CCl4-damaged recipients and observed both
a rise in serum albumin and a histological decrease in
hepatic ﬁbrosis [29]. Similarly, Jiang et al. transplanted
ROSA26 mouse multipotent adult progenitor cells (MAPC)
into nonobese diabetic/severe combined immunodeﬁciency
disease (NOD/SCID) mice sacriﬁcing them 4–24 weeks later.
Recipient livers contained 5–10% donor cells colocalised
with the hepatocyte markers CK18 and albumin. Since there
was no noxious liver injury creating a donor cell survival
advantage,therewasnoincreaseinthenumberofdonorcells
in the 6-month after transplant period [30].
Persistentinjuryhasbeenfoundtoinduceeﬃcienttrans-
diﬀerentiation of BMCs into functional hepatocytes [18].
G r e e nﬂ u o r e s c e n tp r o t e i n -(GFP-) transfected BMCs from
nontreated mice injected into those with liver cirrhosis
induced by CCl4 eﬃciently migrated into the periportal
area of liver lobules after one day, repopulating 25% of
the recipient liver by 4 weeks. In contrast, no GFP-positive
BMCs were detected following transplantation into control
mice with undamaged livers. Serum albumin levels were
signiﬁcantly elevated to compensate for chronic liver failure
in BMC transplantation suggesting that recipient conditions
and microenvironments are key factors for successful cell
therapy using BMCs.
5.ClinicalStudies
Several studies have demonstrated the presence of cells
of bone marrow origin in the human liver. Alison and
colleagues [16] elegantly demonstrated that adult human
liver cells can be derived from stem cells originating in
bone marrow. Analysing livers from female patients who had
received a bone marrow transplantation from a male donor,
they found Y-chromosome- and CK8- positive hepatocytes,
thus, suggesting that extrahepatic stem cells can engraft in
the liver. Theise et al. [31] also studied autopsy and liver
biopsy tissue from recipients of sex-mismatched therapeutic
bone marrow and orthotopic liver transplantations. They
identiﬁed hepatocytes and cholangiocytes of bone marrow
origin by immunocytochemistry staining for CK8, CK18,
and CK19 and FISH analysis for the Y-chromosome. They
found up to 43% of hepatocytes and 38% of cholangiocytes
were engrafted, showing that these cells can be derived
and diﬀerentiated from bone marrow to replenish the liver.
Otherstudies, however, have found lower numbers. Korbling
and associates [32], for example, conﬁrmed bone marrow-
derived hepatocytes in liver biopsies of sex-mismatched
bone marrow transplantation, but these represented only
4%–7% of hepatocytes. Similarly, Ng et al. [33] showed
that only a small proportion of hepatocytes (1.6%) were
recipient derived in the liver allografts. The inconsistency
of these studies may relate to the use of varying techniques
and markers to identify recipient-derived hepatocytes in the
transplanted patients.
Although studies have shown that bone marrow stem
cells can give rise to hepatocytes, the use of bone marrow
stem cells as therapeutic agents is still in its infancy. These
studies generally involve the mobilisation of bone marrow
stem cells using granulocyte colony-stimulating factor (G-
CSF) or infusion of collected bone marrow stem cells, either
peripherallyordirectlyintothehepaticvasculature(Table 1).
Our group conducted a phase I clinical trial of the infusion
of CD34+ cells into the portal vein or the hepatic artery
of ﬁve patients with chronic liver disease with no adverse
eﬀects [34]. Although these patients received relatively low
numbers of cells (2 × 106), a moderate improvement in
serum bilirubin was seen in 3 of the 5 patients which
lasted for more than 18 months [35]. Our experience is
in keeping with the observations made by Am Esch II
and associates, who in their ﬁrst publication demonstrated
increased liver regeneration in 3 patients following intra-
portal administration of autologous CD133+ BM cells into
the left lateral portal vein branches during right portal vein
embolisation (PVE). By CT criteria, left lateral segment
hypertrophy was 2.5-fold higher compared to 3 patients that
had right PVE only [36]. In their second publication, which
included patients from the ﬁrst study, they recruited a total
of 13 patients [37]. There was a signiﬁcant increase in the
daily liver growth in patients who had stem cell infusions in
addition to PVE (n = 6) when compared to patients with
PVE alone (n = 7).
Terai and colleagues have also shown improvement in
liver function following peripheral infusion of autologous
BM cells in patients with liver cirrhosis. Nine patients
who received a peripheral vein infusion of an average of
5.2 × 109 autologous mononuclear cells (CD34+, CD45+,
and ckit+) demonstrated signiﬁcant improvement in the
Child-Pugh Scores and serum levels of albumin. Liver
biopsies were taken in 3 patients revealing an increase
in proliferating cell nuclear antigen staining, an indirect
marker of hepatocyte turnover [38]. Yannaki and associates
have reported 2 patients with alcohol-induced liver cir-
rhosis treated with autologous mobilised HSCs [39]. Each
patient underwent three rounds of G-CSF mobilisation and
peripheral vein infusion of CD34+ cells. The procedure was
well tolerated, and both patients improved their baseline
Child-Turcotte-Pugh (CTP) and model for end-stage liver
disease (MELD) scores during 30 months of followup. A
further 2 patients with hepatitis-B-related decompensated
liver cirrhosis treated with mobilised autologous peripheral
blood monocytes (PBMC) also showed an improvement in
serum albumin, bilirubin, alanine aminotransferase (ALT),
aspartate aminotransferase (AST), and CTP scores for
greater than one year following transfusion [40].
Lyra and associates performed a study on 10 patients
with chronic end-stage liver disease, receiving committed
progenitor cells and no BM cells via the hepatic artery. This
study showed improvement in serum bilirubin, albumin,
and international normalised ratio (INR) [41]. They went
on to perform the ﬁrst randomised controlled study of
autologous BMC transplantation in liver disease [42]. Thirty
patients were randomised to receive either a placebo or
BMC, in the form of an autologous mononuclear cell4 International Journal of Hepatology
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preparation infused into the hepatic artery. After 3 months
followup, the treated patients had a signiﬁcant improvement
in albumin compared to controls (16% versus 2%) and a
signiﬁcant reduction in their Child-Pugh status (−8% versus
+4%). There was no change in the INR between the two
groups. Gasbarrini et al. have also reported the successful
use of autologous CD34+ BMSCs via the portal vein as a
rescue treatment in a patient with drug-induced acute liver
failure [43] .Al i v e rb i o p s yp e r f o r m e da t2 0d a y sf o l l o w i n g
infusion showed increased hepatocyte replication around
necrotic foci; there was also improvement in synthetic liver
function within the ﬁrst 30 days. The patient, however,
died secondary to multiorgan failure related to bacterial
infection. In a study by Khan and colleagues, four patients
with liver insuﬃciency were given G-CSF to mobilise stem
cells. CD34+ cells (0.1 × 108) were injected into the hepatic
artery [44]. All patients showed improvements in serum
albumin, bilirubin, and ALT after one month from the cell
infusion.
In contrast to the previous studies, a trial of 4 patients
with decompensated cirrhosis treated with CD34+ stem
cells via the hepatic artery was stopped prematurely due
to one patient developing nephropathy and hepatorenal
syndrome secondary to radiocontrast [45]. The same group
showed that MSC transplantation in a further 4 patients
with decompensated liver cirrhosis, this time via a peripheral
v e i n ,w a sw e l lt o l e r a t e da n dr e s u l t e di naM E L Ds c o r e
improvement in two [46]. Another study injecting MSC into
either peripheral veins or the portal vein of patients with
ESLD having a MELD score ≥10 (n = 8) showed signiﬁcant
improvement in their MELD score [47]. Kim et al. reported
signiﬁcant improvement in serum albumin, quality of life,
and the Child-Pugh Score in ten patients with advanced liver
cirrhosis due to hepatitis B infection following autologous
bone marrow infusion [48]. Finally, our group has published
the results of administering autologous expanded mobilised
adult BM CD34+ cells via the hepatic artery in 9 patients
with alcoholic liver cirrhosis. Signiﬁcant decreases in serum
bilirubin, ALT, and AST levels were observed, whilst the
Child-PughScoresandradiologicalascitesimprovedin7and
5 patients, respectively [49].
6. Limitationsof Studiesand FutureIssues
Althoughallclinicaltrialstodatehaveshownsomeimprove-
ment in liver function, it must be remembered that the
natural history of cirrhosis tends to be variable. Thus,
one would expect some patients to improve with time,
particularly in compliant patients who can be followed
up and remain abstinent from alcohol. The liver contains
approximately 2.8 × 1011 hepatocytes, and the required
mass of cells to correct a single enzyme biochemical defect
is likely to be signiﬁcantly less than that required for
treatment of chronic or acute liver failure. There is evidence
to suggest that transplantation of only 1–5% of the total
liver mass may be suﬃcient to restore adequate functional
activity [7, 50]. Cells can be delivered to patients via
a peripheral vein, the portal vein, hepatic artery, or an
intrasplenic injection. As both fulminant and chronic, liver
failure requires the replacement of greater than 10% of
functional liver; the cell mass required for transplantation
will be signiﬁcantly higher. The liver cell mass is restored
primarily through division of mature hepatocytes. Stimula-
tionofregeneration,suchasapartialhepatectomy,promotes
increases in carbamoyl phosphate synthetase I activity with
subsequent liver hypertrophy [51]. This early experience
suggests that this therapeutic approach has the potential of
both enhancing and accelerating hepatic regeneration in a
clinical setting.
Unlike hepatocytes, the use of BMSCs for liver regen-
eration does not depend on the procurement of cadaveric
livers whose donors are often immunologically disparate
and also in short supply. The use of adult stem cells is
attractive as it overcomes the moral and ethical barriers of ES
cell manipulation. Further advantages of the use of BMSCs
are that they are multipotent, there is already considerable
experience in their use, they are easily accessible, and there
is unlimited supply. Conversely, concerns have been raised
about the adverse long-term eﬀects of stem cell therapy.
There is evidence to suggest that treatment with BMSCs
may provide liver ﬁbrogenic cells (hepatic stellate cells and
myoﬁbroblasts) which contribute to ﬁbrosis and could have
ad el et e ri o u se ﬀect on already decompensated cirrhotic livers
[52, 53]. Similarly, there are concerns that hepatocellular
carcinoma (HCC) originates from hepatic oval cells and
BMSCs [54]. Much of the data concerning the malignant
potential of BMSCs, however, originates from genetically
modiﬁed rodent models and may not be present in humans
[55].
New ﬁndings in adult stem cell biology are transforming
our understanding of tissue repair raising hopes of successful
regenerative hepatology. Although all clinical trials to date
have shown some improvement in liver function and CD34+
cells have been used safely for BM transplantation for over
20 years, only randomised controlled clinical trials will be
able to fully assess the potential clinical beneﬁt of adult stem
cell therapy for patients with liver insuﬃciency secondary to
ALD.
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